Search Results

ImaginAb, Inc. announced lead selection and progression to IND-enabling studies of IAB56, a minibody designed to target the αvβ6 integrin for use as Lu-177 radiopharmaceutical therapy in solid tumors.

ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam imaging agent and radiopharmaceutical therapies announces a poster presentation at AACR 2023 of an independent analysis undertaken by AstraZeneca, on data from ImaginAb’s IAB-CD8-201 ‘iCorrelate’ Phase II study.

ImaginAb Inc. is pleased to announce the execution of a new non-exclusive License and Supply Agreement with Leucid Bio, a biotech company pursuing a differentiated approach to develop next generation Chimeric Antigen Receptor T-cell therapies using the Company’s proprietary Lateral CAR Platform.

Parthenon Therapeutics and ImaginAb Inc. today announced that the companies have entered into a multi-year, non-exclusive license and supply agreement.

Imaging Endpoints (IE) and ImaginAb announced today that after collaborating for nearly a decade they have entered into a license agreement for IE to directly offer clinical doses of ImaginAb’s CD8 investigational ImmunoPET (zirconium Zr 89 crefmirlimab berdoxam) imaging agent for clinical trials as part of Imaging Endpoints’ industry-leading imaging CRO services.

◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.

BriaCell Therapeutics Corp. jointly announces a multi-year, non-exclusive license agreement with ImaginAb Inc

ImaginAb Inc, a market leading global biotechnology company, focused on developing next generation immuno oncology imaging agents and therapeutic radiopharmaceuticals, announced the signing of a new significant multi-year, non-exclusive license agreement with Boehringer Ingelheim.